Hospitals Don't Follow Patients. They Follow the Rupee.
Cancer will strike about 1.6 million Indians this year. Hypertension already affects 207 million. Yet walk into the boardroom of almost any listed hospital chain and the build plan reads the same way: oncology first. Not diabetes, not hypertension, not primary care. The reason has very little to do with medicine.
Private hospitals do not allocate capacity by where the patients are. They allocate it by where the rupee is densest. Oncology is now the single most profitable specialty in Indian hospitals, and capital is flooding toward it even though cancer affects a sliver of the population next to the chronic diseases of hundreds of millions. That is not a scandal. It is a system doing exactly what it was designed to do, and once you see the design, the whole sector becomes legible.
Hospitals build for the disease that fills a profitable bed, not the disease that fills a waiting room.
The takeaway in one breath
- Hospitals build for the most profitable disease, not the biggest one. Capacity follows revenue density (ARPOB, revenue per occupied bed), not patient need.
- Supply runs opposite to demand. The burden is chronic (NCDs drive 40%+ of hospitalisations and 63–65% of deaths); the build is procedural (oncology, cardiac, transplants, robotics).
- The proof: cancer is ~1.6M new cases a year against ~207M hypertensive Indians (~130x), yet oncology is the No.1 build theme and the most profitable specialty.
- The smoking gun: at Max Healthcare, cardiac is 43% of surgeries but 12% of revenue; oncology is 9% of surgeries but 26% of revenue, its single largest line.
- The catch: 94–97% can't afford targeted therapy, so the people funding the boom can least afford it. The chronic-care gap is a public-financing problem the market will never solve on its own.
Everyone is asking the wrong question
The popular debate is whether oncology is overheating. Wrong question. The useful one is simpler: what single number actually decides what a hospital builds? It is not disease burden. It is ARPOB, average revenue per occupied bed. Once you accept that hospitals optimise for revenue density rather than patient count, oncology stops looking like a clinical choice and starts looking like an arithmetic one. Everything that follows is just the math made visible.
Proof 1: cancer is a rounding error next to the chronic burden
Start with where the patients actually are. India carries roughly 207 million hypertensive adults and about 100 million people with diabetes. New cancer cases run near 1.6 million a year. That is not a small gap. It is a different order of magnitude.
more hypertensive adults than annual new cancer cases
annual growth in cancer incidence, so this is about low volume, not slow growth
This is the trap to avoid: no one is claiming oncology grows slowly. It grows fast. The point is absolute volume. A specialty serving a fraction of the patient base is winning the capital allocation fight. To understand why, you have to look at the one disclosure that gives the game away.
Proof 2: the smoking gun on a single chart
Max Healthcare publishes the share of its complex-surgery volume and the share of its revenue, broken out by specialty. Put the two next to each other and the entire thesis collapses into one picture. Cardiac does the most surgeries and earns a fraction of the money. Oncology does a fraction of the surgeries and earns the most.
Cardiac is 43% of the surgeries and 12% of the revenue. Oncology is the inverse: low volume, yet the single largest revenue line at ~26%.
This is not one company's quirk. It is the pattern across the sector, which is why oncology has quietly become the lead revenue engine.
Proof 3: oncology is now the top revenue specialty
The growth numbers settle it. Across the major chains, oncology is both the fastest-growing and the most profitable line, and management commentary now says so openly.
Fortis oncology revenue growth, year on year (Q1 FY26)
Apollo oncology growth, year on year
HCG oncology revenue growth, year on year
Oncology is now roughly a quarter of Max's in-patient revenue, about 17% at Apollo, and around 16% of Fortis hospital income. The label that industry coverage keeps reaching for is the same one the chart already showed: most profitable specialty in the building.
The mechanism: one number runs every expansion decision
Why does oncology win? Because every expansion decision tracks ARPOB, and high-acuity work carries a structural premium. In FY25 the industry's average daily revenue per occupied bed jumped 23% to about ₹49,304, and the rating agencies attribute the rise directly to oncology, cardiac and robotic procedures.
industry average revenue per occupied bed per day, FY25, up 23% in a year
ARPOB premium that high-acuity care commands over routine work
The deeper reason is that a single cancer patient is not one transaction. It is five, stacked on top of each other, each one billable, each one premium-priced.
Diagnostics & imaging
PET-CT, biopsy, molecular profiling and staging, repeated through the journey.
Surgical oncology
High-ticket OT time, robotics and ICU stays.
Radiation therapy
LINAC cycles running over weeks, at premium pricing.
Medical oncology & drugs
Chemotherapy and immunotherapy, which alone make up 60–70% of the bill.
Long-term follow-up
Surveillance, repeat cycles and survivorship care that keep the relationship billing for years.
A full course of cancer treatment runs ₹2–15 lakh, and immunotherapy alone can cost ₹2–3 lakh a month. Contrast that with a diabetic on metformin or a hypertensive on a daily pill. That patient generates almost no bed-based, procedural revenue. The chronic patient is an OPD and pharmacy relationship. The cancer patient is an admission, five times over.
It is a structural filter, not pure greed
Here is the nuance that makes the argument hold rather than tip into cynicism. Hospitals do not ignore high-volume disease out of indifference. They ignore disease that does not fill a profitable bed, and then they capture the rest only at its most expensive stage.
What gets built
Bed- and procedure-heavy lines: oncology, cardiac, transplants, neuro, renal, robotics. High acuity, high ARPOB, fills tertiary capacity.
What gets skipped
Chronic medical management of diabetes, hypertension and primary respiratory disease. Outpatient, pharmacy and primary-care work with thin per-patient revenue.
How the gap is monetised
Hospitals harvest the complications: the cardiac event, the dialysis session, the stroke. They skip the cheap upstream management and bill the catastrophic downstream event.
The result is a quiet mismatch at the heart of Indian healthcare. Non-communicable diseases already drive more than 40% of hospitalisations and 63–65% of deaths. The burden is overwhelmingly chronic. The build is overwhelmingly procedural.
The catch: the same rupee that funds the boom impoverishes the patient
And this is where the strategy story turns into an equity problem. The economics that make oncology the cleanest bet in the sector also make it ruinous for the people paying the bills.
of cancer patients who could benefit cannot afford targeted or immunotherapy drugs
of a cancer bill is drugs, largely paid out of pocket and outside insurance cover
risk of financial catastrophe in private facilities than in public hospitals
PM-JAY's ₹5 lakh cover helps with inpatient care, but it leaves outpatient drugs and diagnostics, the very layers that carry the bill, largely exposed. So private capacity rushes to the highest-margin disease while the highest-volume diseases stay under-built, and the patients who fund the oncology boom are the ones least able to pay for it.
So what: three readings of the same data
For investors
Oncology is the cleanest ARPOB-accretive bet in the sector. Watch radiation-bunker commissioning and oncology revenue share as the leading indicators of margin expansion, ahead of headline bed counts.
For operators
Build the referral engine before the bunker. Tumour boards, pathology, imaging and day-care chemo come first; LINAC and transplant come last. Lead with the system, not the machine.
For policy
The market will not build for diabetes, hypertension or primary care on its own, because there is no bed-based margin in it. That gap is a public-financing problem, not a market one, and no amount of private capex will close it.
Capacity follows revenue density. Oncology is the proof. The chronic burden is the cost, and right now nobody owns it.